Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis

Table 3

The univariate and multivariate analyses in the ICIs cohort: OR for DCR.

Variable	Univariate		Multivariate
	OR (95% CI)	value	OR (95% CI)	value
Age (year)
<65	1
≥65	0.46 (0.17–1.24)	0.125
Smoking status
Nonsmoker	1
Smoker	1.79 (0.57–5.66)	0.323
Metastatic sites number
<2	1
≥2	2.11 (0.78–5.75)	0.142
ICIs drug
Sintilimab	1
Nivolumab	5.63 (0.65–9.82)	0.117
Pembrolizumab	3.75 (0.46–8.32)	0.216
ICIs treatment modality
Monotherapy	1
Combination therapy	0.56 (0.22–1.39)	0.207
ICIs line
1	1		1
≥2	4.10 (1.36–9.30)	0.018	5.99 (1.29–9.71)	0.022
Histology
Nonsquamous	1
Squamous	1.32 (0.54–3.23)	0.547
Stage
I–IIIA	1
IIIB–IV	1.43 (0.30–6.75)	0.654
RDW (%)
<16	1
≥16	0.95 (0.25–3.56)	0.936
ALB (g/L)
≥35	1		1
<35	5.63 (2.01–8.73)	0.001	5.52 (1.89–9.18)	0.002
dNLR
≤3	1
>3	1.89 (1.69–5.15)	0.213
PLR
≥160	1
<160	0.71 (0.29–1.74)	0.449